
    
      This was a sham controlled study for the first three months. Patients had one eye designated
      as the study eye and were randomized to receive one of two study treatments (CXL or sham) in
      their study eye. The patients were evaluated at 1, 3, 6, and 12 months. At month 3 or later
      patients had the option of receiving CXL treatment in both the sham and non-study eye.
    
  